The field of the present disclosure relates generally to medical devices. More specifically, the present disclosure relates to caps for medical connectors. In some embodiments, the present disclosure relates to caps that can be used to protect the sterility of open medical connectors.
The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. The drawings depict only typical embodiments, which embodiments will be described with additional specificity and detail in connection with the drawings in which:
Patients undergoing various treatments may receive a central vascular catheter. Exposure of such catheters to foreign bodies increases the risk of catheter-related bloodstream infections. Infections associated with central venous catheters are categorized as either central-line associated bloodstream infections or catheter-related bloodstream infections. These infections can increase hospital costs and length of stay. The costs to hospitals and the health care system from these infections are substantial in terms of both morbidity and resources expended.
In the detailed description, reference is made to the accompanying drawings which form a part hereof and in which are shown, by way of illustration, specific embodiments of the disclosure. These embodiments are described in sufficient detail to enable those of ordinary skill in the art having the benefit of this disclosure to practice the present disclosure, and it is to be understood that other embodiments may be utilized, and that structural, logical, and electrical changes may be made within the scope of the disclosure. From the following descriptions, it should be understood that components of the embodiments as generally described and illustrated in the figures herein could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the disclosure, but is merely representative of various embodiments. While the various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
In this description, specific implementations are shown and described only as examples and should not be construed as the only way to implement the present disclosure unless specified otherwise herein. It will be readily apparent to one of ordinary skill in the art having the benefit of this disclosure, for example, that the various embodiments of the present disclosure may be practiced with numerous types and forms of medical connectors. The devices and methods described herein could be useful in a number of environments that employ conduits or connectors, for example, the present disclosure may be practiced in any situation that uses at least one connector with a luer end.
It should be understood that any reference to an element herein using a designation such as “first,” “second,” and so forth does not limit the quantity or order of those elements, unless such limitation is explicitly stated. Rather, these designations may be used herein as a convenient method of distinguishing between two or more elements or instances of an element. Thus, a reference to first and second elements does not mean that only two elements may be employed there or that the first element must precede the second element in some manner. Also, unless stated otherwise a set of elements may comprise one or more elements.
The phrases “connected to” and “coupled to” refer to any form of interaction between two or more entities, including mechanical, electrical, magnetic, electromagnetic, fluid, and thermal interaction. Two components may be connected or coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to each other through an intermediate component.
The directional terms “proximal” and “distal” are used herein to refer to opposite locations on a medical device. The proximal end of the device is defined as the end of the device closest to the end-user when the device is in use by the end-user. The distal end is the end opposite the proximal end, along the longitudinal direction of the device, or the end furthest from the end-user.
Referring in general to the following description and accompanying drawings, various embodiments of the present disclosure are illustrated to show its structure and method of operation. Common elements of the illustrated embodiments may be designated with similar reference numerals. Accordingly, the relevant descriptions of such features apply equally to the features and related components among all the drawings. Any suitable combination of the features, and variations of the same, described with components illustrated in
One embodiment of the present disclosure comprises a cap for a medical connector. The medical connector may have a luer connector. The cap may further comprise a disinfecting agent. In some embodiments the cap comprises a chamber containing the disinfecting agent. When an end-user attaches the cap comprising the disinfecting agent to the luer connector it applies the disinfectant to the open end of the luer connector. The open end of the cap is configured to connect to a medical connector such as a luer connector. In some embodiments the cap is configured to engage with a female luer connector, and in other embodiments the cap is configured to a male luer connector. For example, the cap may be configured with threads to engage a medical connector such as a male or female luer connector. In some embodiments these threads are configured with a hard stop to prevent an end-user from over rotating the cap. Additionally or alternatively, the threads may be configured to provide sufficient rotation of the cap with respect to a connector to dispense an adequate amount of antiseptic fluid to provide effective disinfection.
The cap may comprise a chamber which has a chamber inner lumen. Within the cap chamber the cap may further comprise a reservoir and an insert. The insert is disposed in the chamber lumen and comprises a first end which is shaped to engage with the open end of a medical connector such as a luer connector. This shape may be dome shaped, a frusto-conical shape, or any other shape which may seal or partially seal the open end of a medical connector to reduce fluid entering the lumen of the medical connector while maximizing the flow of fluid around the insert and the outer surfaces of the medical connector.
In some embodiments the cap is configured to facilitate alignment of the insert with the open end of a medical connector. For example, the insert may be disposed within the cap such that threads of the cap tend to align the insert and a medical connector during coupling of the cap and medical connector. The insert may thus tend to engage flush with the open end of a luer connector. In some embodiments the insert may engage substantially perpendicular to the open end of the luer so that the entire circumference of the open end of the luer connector engages substantially simultaneously with the insert. Engaging substantially simultaneously around the entire circumference of the open end of the luer connector may, in turn, reduce or minimize an antiseptic fluid from flowing into the inner luminal space of the luer connector when it engages with the cap.
The insert may also comprise an annular gap that allows an antiseptic fluid to flow around the insert and interact with the surface of the dome shaped first end of the insert during coupling of a cap and a medical connector. As the cap engages with the medical connector radial expansion of the insert may tend to reduce or eliminates this gap reducing or eliminating the amount of antiseptic fluid which can flow around the insert and interact with the medical connector.
Some caps within the scope of this disclosure may be configured to hold 45 pounds per square inch (PSI) of pressure.
The insert may further comprise a second end which is configured to deform when an end-user, such as a health care worker, engages the cap onto a medical connector. As the medical connector, such as the luer connector, is engaged with the cap the open end of the luer connector exerts axial force against the insert. In some embodiments, the insert second end deforms radially as the insert moves axially. The inner walls of the cap chamber may limit the degree the insert second end is able to deform under this axial force. In some embodiments, when the end-user disengages the cap from the luer connector, the insert second end begins to assume its original shape. In this way the insert may move like a spring axially within the cap chamber. When the insert springs back into its original shape it may thus maintain an axial force against the luer connector open end until the luer connector fully disengages from the cap. As the cap is disengaged in this manner the seal or partial seal is maintained between the insert first end and the open end of the luer connector, minimizing the amount of fluid that is able to enter the open end of the luer connector. This second end of the insert may be thought of as a controlled-deformation segment and serves to provide axial force against the medical connector which has been engaged with the cap. In some embodiments the insert second end may comprise external ribs that contact protrusions on the internal sidewall of the cap chamber. The cap is reusable, for example, configured with an insert that is able to deform and spring back into its original shape multiple times, or the cap may be configured as a single use device. The cap second end is further configured to be grasped comfortably and securely by an end-user, such as a health care worker.
In some embodiments the cap chamber further comprises a reservoir configured to absorb fluid, such as disinfectant antiseptic fluid. In some embodiments the reservoir is polyester urethane foam. In some embodiments the polyester urethane foam has a density of between 0.5 and 4 lbs/ft3. In some embodiments the polyester urethane foam has a density of between 1 and 3 lbs/ft3. In some embodiments the polyester urethane foam has a density of 2 lbs/ft3. In some embodiments the reservoir surrounds the insert. In alternative embodiments the reservoir is in a hollow portion of the insert. In some embodiments the reservoir is axially distal to the insert, in other words further from the open cap first end. In some embodiments the reservoir is axially proximal to the insert, in other words closer to the open cap first end. In some embodiments the reservoir is in contact with the insert first end. In some embodiments the reservoir is in contact with the insert second end.
Various materials are within the scope of this disclosure. For example, the insert may be comprised of various polymeric and/or elastomeric materials, including silicones, isoprene, neoprene, Santoprene, and so forth. The reservoir may comprise various foam materials, including polyester urethane foam as discussed above. The reservoir may also comprise an elastomeric material, including elastomers including pores or other structures capable of absorbing a liquid antiseptic agent. The reservoir may be a non-particulate elastomer configured to reduce or minimize breakdown of the reservoir that may result in particles within the cap or connector. Embodiments wherein the insert comprises a hollow portion or void with no separate component was a reservoir (such as embodiments wherein a void within an elastomeric insert is configured to act as a reservoir for an antiseptic fluid) are also within the scope of this disclosure.
The cap chamber may contain a disinfectant, such as an antiseptic. In some embodiments this antiseptic may be an antiseptic fluid such as isopropyl alcohol, hydrogen peroxide, chlorhexidine gluconate, iodophor, povidone iodine, or any other suitable antiseptic. In some embodiments the antiseptic is not fluid but in the form of disinfectant beads, such as hydrogel beads, disinfectant foam, or a loaded polymer. In some embodiments the antiseptic is sequestered in the cap chamber within a first closed compartment by a breakable seal, such as a foil seal. This foil seal will stay intact until an end-user engages the cap with a medical connector which then may exert axial pressure on the cap insert. Alternatively, a foil seal may be disposed across the cap chamber such that an end-user can peel off or otherwise remove the foil seal prior to use. The cap insert may then deform, exerting radial force which can then break the seal holding the antiseptic, releasing it into the cap chamber. In this way, the antiseptic is released and surrounds the insert and the outer surfaces of the medical connector while minimizing the amount of antiseptic that enters the luer connector open end which is loosely sealed by the cap insert first end. In some embodiments the antiseptic is soaked into the reservoir, and when the cap insert is pushed axially it compresses the reservoir, releasing the antiseptic into the chamber and similarly surrounding the insert and the outer surfaces of the medical connector. In some embodiments the antiseptic fluid is both in an absorbent reservoir and sequestered in a breakable seal within the cap chamber inner lumen.
In some embodiments when the end-user disengages the cap from the medical connector, the insert returns to its original shape, which increases the volume within the cap chamber. As the insert returns to its original shape the reservoir will expand, increasing the volume of fluid, such as antiseptic fluid, the reservoir can hold. As the reservoir expands it creates a vacuum or partial vacuum acting on the fluid, thus tending to draw in and absorb the fluid which had been surrounding the insert and the outer surfaces of the medical connector. In this way as the cap is disengaged from the medical connector the amount of fluid in contact with the outer surface of the medical connector decreases, which serves to further reduce the amount of fluid that enters the open end of the medical connector as it is fully disengaged from the cap and the insert first end.
In some embodiments the cap insert may be configured to store the antiseptic within the insert. For example, the insert may be hollow with side apertures to permit the antiseptic agent to flow out of the insert when axial force is exerted on the insert from the end-user attaching a medical connector to the cap. In some embodiments the insert first end may inhibit flow of fluid, such as an antiseptic fluid into the lumen of an engaged medical connector while allowing flow to specific regions on or in the medical connector. In some embodiments the insert is made of a single material. In alternative embodiments the insert first end is made of material different from the insert second end. In some embodiments the insert first end is reinforced to reduce deformation when axial force is applied to the insert when an end-user attaches a medical connector to the cap. In some embodiments the cap is configured with radial protrusions to maintain the insert in the cap chamber.
In some embodiments the method of capping a medical connector with a cap, as described above, is disclosed herein. The end-user may obtain a cap, as described above. If a foil seal is present, the end-user may peels off a foil seal from an end of the cap to open the cap chamber. The end-user may then connect the cap to the open end of the medical connect and twist either the cap to fully engage the cap on the connector or the connector to fully engage the cap. The cap will then disinfect, as described above, the outer surface of the medical connector while minimizing the amount of disinfectant that enters the open end of the medical connector. In some embodiments the cap may be configured with threading to engage the medical connector. In some embodiments these threads, or an end of these threads, are configured with a hard stop to prevent the end-user from over rotating the cap on the medical connector. In some embodiments the cap is configured to engage with a female luer connector. In alternative embodiments the cap is configured to engage with a male luer connector. In some embodiments the end of the cap is sealed with a sterile seal which is removable by the end-user just before it is attached to the medical connector.
In some embodiments the means for minimizing medical connector infections is provided by applying a cap, as described above, to a medical connector. The cap applies an antiseptic agent to a medical connector. In some embodiments, the cap has engagement means to attach to a male luer connector. In some embodiments, the cap comprises the means for limiting or minimizing the flow of antiseptic in the cap chamber as the end-user engages the open end of a medical connector with the cap, while at the same time maximizing the flow of antiseptic to the outer surface of the medical connector. In some embodiments the cap comprises an insert in the chamber, the insert comprising the means to exert axial force against the open end of the medical connector as the cap is both engaged and disengaged with the medical connector. In some embodiments the cap is configured with a means of maintaining the insert in the cap chamber.
The insert 102 also comprises an insert body 108 between the insert first end 104 and an insert second end 110. In this embodiment the insert second end 110 is configured to deform under axially applied pressure. In this embodiment the insert first end 104 is reinforced with the insert reinforcement 106 to reduce deformation of the insert first end 104 and the insert body 108 under axially applied pressure. In the depicted embodiment, the reservoir 112 comprises a reservoir hole 113 through which the insert second end 110 and the insert body 108 may be pushed. The insert first end 104 further serves to limit the distance the insert 102 can be pushed through the reservoir hole 113. The insert reinforcement 106 may in some embodiments be configured to further limit the position the insert 102 takes within the reservoir 112.
The cap 200 comprises the cap body 220 and a cap first end 216. The cap first end 216 comprises a cap opening 214. The cap first end 216 is further configured to engage a male luer connector with threads 218. An insert first end 204 is visible through the cap opening 214.
As noted above,
In the first configuration, shown in
The insert first end 804 of the insert 802 may be dome shaped, with a hemispherical shape to engage and seal or partially seal the open end of a female luer connector (not depicted). Additionally or alternatively, the insert first end 804 of the insert 802 may be configured to partially conform to the shape of a portion of the luer to facilitate sealing. In some embodiments the insert 802 is disposed within the cap 800 such that the ridges 818, in threaded engagement with a luer, tend to align the insert 802 and the luer before the insert first end 804 of the insert 802 engages the open end of the luer. Additionally, in some embodiments the insert 802 comprises an insert second end 810 which is open and configured to accept a reservoir such as the reservoir 812 within the insert 802.
In some embodiments, the cap 800 is configured such that there is an annular gap 805 between the insert 802 and the cap 800 when the insert 802 is unconstrained. This annular gap 805 may allow an antiseptic fluid to flow around the insert 802, for example, from the reservoir 812 adjacent the insert second end 810 of the insert 802. Thus, the annular gap 805 may allow antiseptic fluid from the reservoir 812 to interact with the insert first end 804 and then come into contact with the luer end (not depicted) during coupling of a luer and the cap 800. In some embodiments when the luer cap is partially or fully engaged with the cap 800 a compressive force exerted on the insert 802 by the luer may cause the insert 802 to radially expand, thus reducing or closing the annular gap 805. This, in turn, may reduce or eliminate the antiseptic fluid flow around the insert 802, which may limit excess antiseptic fluid from entering the luer end.
As shown in
Kits that include a medical connector cap are also within the scope of this disclosure. For example, a kit may include any of the devices described above. The kit may also include other elements, such as instructions for using the devices. Kits may additionally or alternatively include (1) male luer connector caps; (2) female luer connector caps; (3) double-ended luer connector caps; (4) sterile gloves; (5) sterile barrier; (6) antiseptic swabs; and (7) sterile gauze, among other potential elements.
Any methods disclosed herein include one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified. Moreover, sub-routines or only a portion of a method described herein may be a separate method within the scope of this disclosure. Stated otherwise, some methods may include only a portion of the steps described in a more detailed method.
Reference throughout this specification to “an embodiment” or “the embodiment” means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the quoted phrases, or variations thereof, as recited throughout this specification are not necessarily all referring to the same embodiment.
Similarly, it should be appreciated by one of skill in the art with the benefit of this disclosure that in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim requires more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following this Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims.
Recitation in the claims of the term “first” with respect to a feature or element does not necessarily imply the existence of a second or additional such feature or element. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the present disclosure.
While the disclosure is susceptible to various modifications and implementation in alternative forms, specific embodiments have been shown by way of non-limiting example in the drawings and have been described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the disclosure includes all modifications, equivalents, and alternatives falling within the scope of the disclosure as defined by the following appended claims and their legal equivalents.
Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the present disclosure to its fullest extent. The examples and embodiments disclosed herein are to be construed as merely illustrative and exemplary and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having skill in the art, and having the benefit of this disclosure, that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure herein.
Disinfecting caps for open female connectors were tested with stopcock connectors to observe alcohol ingress into the lumen of the stopcock connector. Testing did not show alcohol ingress but reflected evidence of the insert protruding for up to 1 mm into the lumen of the connector. As discussed above,
A layer of the tungsten powder 970 was dusted into the inner luminal surface 935 of the luer connector 932 to act as the contrast agent, as the tungsten powder 970 would get disrupted when it encountered alcohol during testing of coupling and uncoupling of the luer connector 932 and the cap 900.
Luer connectors 932 dusted with a tungsten powder 970 (in the configuration shown in
The caps 900 were found to maintain contact with the opening 934 of the luer connector 932 as the insert 902 in the cap 900 deformed to maintain pressure at the insert 902—the opening 934 interface. This seal prevented alcohol from contact with the inner luminal surface 935 of the luer connector 932. Tungsten particles were observed to be displaced (as shown in
This application is a continuation of U.S. patent application Ser. No. 15/874,505, filed on Jan. 18, 2018 and titled, “Disinfecting Luer Cap and Method of Use,” which claims priority to U.S. Provisional Application No. 62/560,808, filed on Sep. 20, 2017 and titled, “Disinfecting Luer Cap and Method of Use,” and U.S. Provisional Application No. 62/451,298, filed on Jan. 27, 2017 and titled, “Disinfecting Caps for Open Luer Connectors,” all of which are hereby incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
1744026 | Baltzley | Oct 1926 | A |
1868200 | Freedman | Jul 1932 | A |
2299037 | Saueressig | Oct 1942 | A |
2351804 | Blum | Jun 1944 | A |
2356969 | Blum | Aug 1944 | A |
2472921 | Quimper | Jun 1949 | A |
2994420 | Fobias | Aug 1961 | A |
3315830 | Flynn | Apr 1967 | A |
3431548 | Busler | Mar 1969 | A |
3446596 | Salivar et al. | May 1969 | A |
3976311 | Spendlove | Aug 1976 | A |
3987930 | Fuson | Oct 1976 | A |
4121727 | Robbins et al. | Oct 1978 | A |
4232677 | Leibinsohn | Nov 1980 | A |
4299330 | Walter | Nov 1981 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4340052 | Dennehey et al. | Jul 1982 | A |
4346703 | Dennehey et al. | Aug 1982 | A |
4354490 | Rogers | Oct 1982 | A |
4369781 | Gilson et al. | Jan 1983 | A |
4402691 | Rosenthal et al. | Sep 1983 | A |
4432764 | Lopez | Feb 1984 | A |
4432766 | Bellotti et al. | Feb 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4450624 | Collier | May 1984 | A |
4572373 | Johansson | Feb 1986 | A |
4597758 | Aalto et al. | Jul 1986 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4667837 | Vitello et al. | May 1987 | A |
4671306 | Spector | Jun 1987 | A |
4778447 | Velde et al. | Oct 1988 | A |
4798303 | Arnold | Jan 1989 | A |
4810241 | Rogers | Mar 1989 | A |
4838875 | Somor | Jun 1989 | A |
D303631 | Demarest | Sep 1989 | S |
D310542 | Regnault | Sep 1990 | S |
4991629 | Ernesto et al. | Feb 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5165559 | Kusz | Nov 1992 | A |
5184742 | Decaprio et al. | Feb 1993 | A |
D333788 | Geschwender | Mar 1993 | S |
5190534 | Kendell | Mar 1993 | A |
5195957 | Tollini | Mar 1993 | A |
5205821 | Kruger et al. | Apr 1993 | A |
5242425 | White et al. | Sep 1993 | A |
D340112 | Zeman | Oct 1993 | S |
D341227 | Lang et al. | Nov 1993 | S |
5269771 | Thomas et al. | Dec 1993 | A |
5385372 | Utterberg | Jan 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5445270 | Dratz | Aug 1995 | A |
5451113 | Lund et al. | Sep 1995 | A |
5466219 | Lynn et al. | Nov 1995 | A |
5492147 | Challender et al. | Feb 1996 | A |
5536258 | Folden | Jul 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5593055 | Repp et al. | Jan 1997 | A |
5599307 | Pacher et al. | Feb 1997 | A |
5620427 | Werschmidt et al. | Apr 1997 | A |
5624057 | Lifshey | Apr 1997 | A |
5674198 | Leone | Oct 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5738663 | Lopez | Apr 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5833658 | Levy et al. | Nov 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5893841 | Glickman | Apr 1999 | A |
5894015 | Rechtin | Apr 1999 | A |
5951519 | Utterberg | Sep 1999 | A |
5954657 | Rados | Sep 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
5964978 | Hirooka | Oct 1999 | A |
6045539 | Menyhay | Apr 2000 | A |
6117105 | Bresnaham et al. | Sep 2000 | A |
6152913 | Feith et al. | Nov 2000 | A |
6171287 | Lynn et al. | Jan 2001 | B1 |
D456668 | Tse | May 2002 | S |
D468015 | Horppu | Dec 2002 | S |
D470888 | Kuboshima | Feb 2003 | S |
6523686 | Bae | Feb 2003 | B1 |
6695160 | Culley et al. | Feb 2004 | B1 |
6753114 | Jacobs et al. | Jun 2004 | B2 |
6932795 | Lopez et al. | Aug 2005 | B2 |
6960191 | Howlett et al. | Nov 2005 | B2 |
7014169 | Newton et al. | Mar 2006 | B2 |
7040598 | Raybuck | May 2006 | B2 |
7040669 | Kenmotsu et al. | May 2006 | B2 |
7100796 | Orr et al. | Sep 2006 | B1 |
7198611 | Connell et al. | Apr 2007 | B2 |
D545964 | Blanco | Jul 2007 | S |
D547446 | Racz et al. | Jul 2007 | S |
D550355 | Racz et al. | Sep 2007 | S |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7316669 | Ranalleiia | Jan 2008 | B2 |
D573643 | Brigham et al. | Jul 2008 | S |
7452592 | Cowton | Nov 2008 | B2 |
D607325 | Rogers et al. | Jan 2010 | S |
7762524 | Cawthon et al. | Jul 2010 | B2 |
7762988 | Vitello | Jul 2010 | B1 |
7763006 | Tennican | Jul 2010 | B2 |
7780794 | Rogers et al. | Aug 2010 | B2 |
D632574 | Huntington et al. | Feb 2011 | S |
7922701 | Buchman | Apr 2011 | B2 |
D639421 | Sano et al. | Jun 2011 | S |
7985302 | Rogers et al. | Jul 2011 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8172825 | Solomon et al. | May 2012 | B2 |
8177761 | Howlett et al. | May 2012 | B2 |
8197749 | Howlett et al. | Jun 2012 | B2 |
8231587 | Solomon et al. | Jul 2012 | B2 |
8231602 | Anderson et al. | Jul 2012 | B2 |
8273303 | Ferlic et al. | Sep 2012 | B2 |
8328767 | Solomon et al. | Dec 2012 | B2 |
8343112 | Solomon et al. | Jan 2013 | B2 |
8419713 | Solomon et al. | Apr 2013 | B1 |
8523830 | Solomon et al. | Sep 2013 | B2 |
8523831 | Solomon et al. | Sep 2013 | B2 |
8641681 | Solomon et al. | Feb 2014 | B2 |
8647308 | Solomon et al. | Feb 2014 | B2 |
8647326 | Solomon et al. | Feb 2014 | B2 |
8740864 | Hoang | Jun 2014 | B2 |
8784388 | Charles et al. | Jul 2014 | B2 |
8808637 | Ferlic | Aug 2014 | B2 |
8961475 | Solomon et al. | Feb 2015 | B2 |
9079692 | Solomon et al. | Jul 2015 | B2 |
9101750 | Solomon et al. | Aug 2015 | B2 |
9114915 | Solomon et al. | Aug 2015 | B2 |
9242084 | Solomon et al. | Jan 2016 | B2 |
9283369 | Ma et al. | Mar 2016 | B2 |
9352140 | Kerr et al. | May 2016 | B2 |
10975208 | Pekala et al. | Apr 2021 | B2 |
20020093192 | Matkovich | Jul 2002 | A1 |
20030140441 | Stafford | Jul 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20030181849 | Castellanos | Sep 2003 | A1 |
20030198502 | Maloney et al. | Oct 2003 | A1 |
20040010909 | Emanuel et al. | Jan 2004 | A1 |
20040039341 | Ranalletta | Feb 2004 | A1 |
20040195136 | Young et al. | Oct 2004 | A1 |
20040201216 | Segal et al. | Oct 2004 | A1 |
20040214316 | O'Connell | Oct 2004 | A1 |
20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
20050033267 | Decaria | Feb 2005 | A1 |
20050038397 | Newton et al. | Feb 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050183971 | Petricca | Aug 2005 | A1 |
20050203460 | Kim | Sep 2005 | A1 |
20050245883 | Baldwin | Nov 2005 | A1 |
20050265773 | De Laforcade | Dec 2005 | A1 |
20050266714 | Higgins et al. | Dec 2005 | A1 |
20060030827 | Raulerson et al. | Feb 2006 | A1 |
20060177250 | Nakagaki | Aug 2006 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070282280 | Tennican | Dec 2007 | A1 |
20070287989 | Crawford et al. | Dec 2007 | A1 |
20070292750 | Beard | Dec 2007 | A1 |
20070293818 | Stout et al. | Dec 2007 | A1 |
20070293822 | Crawford et al. | Dec 2007 | A1 |
20080019889 | Rogers et al. | Jan 2008 | A1 |
20080021381 | Lurvey et al. | Jan 2008 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updefraff et al. | Feb 2008 | A1 |
20080038167 | Lynn | Feb 2008 | A1 |
20080039803 | Lynn | Feb 2008 | A1 |
20080097407 | Plishka | Feb 2008 | A1 |
20080086091 | Anderson et al. | Apr 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080105704 | Pritchard | May 2008 | A1 |
20080107564 | Sternberg et al. | May 2008 | A1 |
20080132880 | Buchman | Jun 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080190485 | Guala | Aug 2008 | A1 |
20080221552 | Leonard | Sep 2008 | A1 |
20080235888 | Vaillancourt et al. | Oct 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090099529 | Anderson et al. | Apr 2009 | A1 |
20090149819 | Chelak | Jun 2009 | A1 |
20090205151 | Fisher et al. | Aug 2009 | A1 |
20090287160 | Sudo et al. | Nov 2009 | A1 |
20100003067 | Shaw et al. | Jan 2010 | A1 |
20100047123 | Solomon et al. | Feb 2010 | A1 |
20100049170 | Solomon et al. | Feb 2010 | A1 |
20100063482 | Mansour et al. | Mar 2010 | A1 |
20100058201 | Hattangadi et al. | Apr 2010 | A1 |
20100100056 | Cawthon et al. | Apr 2010 | A1 |
20100242993 | Hoang et al. | Sep 2010 | A1 |
20100285348 | Murata et al. | Nov 2010 | A1 |
20100306938 | Rogers et al. | Dec 2010 | A1 |
20100313366 | Rogers et al. | Dec 2010 | A1 |
20110044850 | Solomon et al. | Feb 2011 | A1 |
20110054440 | Lewis | Mar 2011 | A1 |
20110064512 | Shaw et al. | Mar 2011 | A1 |
20110064515 | Ruckey et al. | Mar 2011 | A1 |
20110165020 | Truggvason | Jul 2011 | A1 |
20110198935 | Hinman et al. | Aug 2011 | A1 |
20110213341 | Solomon et al. | Sep 2011 | A1 |
20110217212 | Solomon et al. | Sep 2011 | A1 |
20110232020 | Rogers et al. | Sep 2011 | A1 |
20110265825 | Rogers et al. | Nov 2011 | A1 |
20110277788 | Rogers et al. | Nov 2011 | A1 |
20110290754 | Taber et al. | Dec 2011 | A1 |
20110314619 | Schweikert | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120028104 | Brant et al. | Feb 2012 | A1 |
20120039764 | Solomon | Feb 2012 | A1 |
20120039765 | Solomon | Feb 2012 | A1 |
20120082977 | Rajagopal et al. | Apr 2012 | A1 |
20120145468 | Ekala et al. | Jun 2012 | A1 |
20120164513 | Peng et al. | Jun 2012 | A1 |
20120216359 | Rogers et al. | Aug 2012 | A1 |
20120281444 | Dent | Nov 2012 | A1 |
20120326516 | Gurunathan et al. | Dec 2012 | A1 |
20130019421 | Rogers et al. | Jan 2013 | A1 |
20130072908 | Solomon et al. | Mar 2013 | A1 |
20130171030 | Ferlic et al. | Jul 2013 | A1 |
20130197485 | Gardner et al. | Aug 2013 | A1 |
20130224555 | Hong et al. | Aug 2013 | A1 |
20130234520 | Dierksheide et al. | Sep 2013 | A1 |
20130299445 | Cerracchio | Nov 2013 | A1 |
20140001182 | Wood et al. | Jan 2014 | A1 |
20140010481 | Last et al. | Jan 2014 | A1 |
20140135739 | Solomon et al. | May 2014 | A1 |
20140227144 | Liu et al. | Aug 2014 | A1 |
20140360968 | Barth | Dec 2014 | A1 |
20150217106 | Banik et al. | Aug 2015 | A1 |
20150229131 | Gerhardinger | Aug 2015 | A1 |
20150231384 | Ma et al. | Aug 2015 | A1 |
20150273199 | Adams et al. | Oct 2015 | A1 |
20150374968 | Solomon et al. | Dec 2015 | A1 |
20160028067 | Pekala et al. | Jan 2016 | A1 |
20160038701 | White et al. | Feb 2016 | A1 |
20160045629 | Gardner et al. | Feb 2016 | A1 |
20160106968 | Solomon et al. | Apr 2016 | A1 |
20160236852 | Albrecht | Aug 2016 | A1 |
20170033564 | Lin et al. | Feb 2017 | A1 |
20170245618 | Chen et al. | Aug 2017 | A1 |
20190099593 | Avula et al. | Apr 2019 | A1 |
20190209781 | Solomon et al. | Jul 2019 | A1 |
20190386274 | Wood et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
104157819 | Nov 2014 | CN |
205549223 | Sep 2016 | CN |
0084695 | Aug 1983 | EP |
0229789 | Jul 1987 | EP |
0229786 | Mar 1990 | EP |
0462355 | Dec 1991 | EP |
64002760 | Jan 1989 | JP |
1020120057560 | Jun 2012 | KR |
1020150131300 | Nov 2015 | KR |
2002089899 | Nov 2002 | WO |
2004035245 | Apr 2004 | WO |
2006099306 | Sep 2006 | WO |
2007097985 | Aug 2007 | WO |
2008089196 | Jul 2008 | WO |
2008100950 | Aug 2008 | WO |
2010002808 | Jan 2010 | WO |
2010141508 | Dec 2010 | WO |
2011141508 | Dec 2010 | WO |
2011053924 | May 2011 | WO |
2011066565 | Jun 2011 | WO |
2011066586 | Jun 2011 | WO |
2011147508 | Dec 2011 | WO |
2013184716 | Dec 2013 | WO |
2014145849 | Sep 2014 | WO |
2015174953 | Nov 2015 | WO |
2016031466 | Mar 2016 | WO |
2017158555 | Sep 2017 | WO |
2017160892 | Sep 2017 | WO |
Entry |
---|
Office Action dated Oct. 14, 2020 for U.S. Appl. No. 16/150,966. |
European Search Report dated Jun. 28, 2021 for EP18865254.9. |
Baxa Corporation Launches PadLock Set Saver for IV Safety press release, 2 pages, available at http://www.pr.com/press—release/55432, Oct. 10. 2007. |
Baxa Corporation Padlock catalog, 3 pages, copyright 2009, available at http://www.baxa.com/SearchResults/ProductDetail/?id=6452BFB9-3048-7B87-701697FB93902BA6. |
Baxa Corporation Padlock Microbial Testing Technical Paper, copyright 2007, 4 pages, available at http://www.baxa.com/resources/docs/technicalPapers/PadLockMicrobialChallengeTechPaper.pdf. |
Baxa Corporation PadLock Set Saver Specifications and Instructions for Use, copyright 2007, 2 pages, available at http://www.baxa.com/resources/docs/5300103905C.pdf. |
BD Q-Syte Luer Access Split Septum product brochure, 4 pages, available at http://www.bd.com/infusion/pdfs/D16333.pdf. ,Nov. 2008. |
Braun product catalog, 2pages. ,Aug. 2008. |
Curos Port Protector product brochure, 2 pages, available at http://www.iveramed.com/clocs/Curos%20Brochure-FINAL.pdf. ,Nov. 2008. |
Hospira Male/Female Sterile Cap product packaging insert and brochure, 2 pages. ,Aug. 2004. |
Kippmed Vented Non-Vented Female Luer Lock Caps, The KippGroup, ,Jan. 1995 ,2 pgs. |
Tego Connector product brochure, 2 pages, available at http://www.icumed.com/Docs-Tego/M1-1148%20TEG0%20Folder%20Brochure%20Rev.3.pdf. ,Nov. 2008. |
Unomedical Medical Products catalog, 2 pages, available at http://www.unomedical.net/au/section05/section10/LocalSSI/..%5C..%5Cpdf%5Cmedical.pdf ,Jan. 2006. |
European Search Report dated Mar. 6, 2012 for EP08727689.5. |
European Search Report dated Mar. 25, 2020 for EP15808498.8. |
European Search Report dated Jun. 13, 2019 for EP16866954.7. |
European Search Report dated Jun. 20, 2017 for EP10827614.8. |
International Search Report and the Written Opinion dated Jan. 26, 2011 for PCT/US2010/058404. |
International Search Report and Written Opinion dated Jan. 6, 2011 for PCT/US2010/054995. |
International Search Report and Written Opinion dated Jan. 24, 2019 for PCT/US2018/054202. |
International Search Report and Written Opinion dated Feb. 1, 2017 for PCT/US2016/062061. |
International Search Report and Written Opinion dated Feb. 7, 2011 for PCT/US2010/058453. |
International Search Report and Written Opinion dated Jun. 22, 2018 for PCT/US2018/014237. |
International Search Report and Written Opinion dated Aug. 1, 2008 for PCT/US2008/051087. |
International Search Report with Written Opinion dated Aug. 31, 2009 for PCT/US2009/049094. |
Notice of Allowance dated Jun. 7, 2017 for U.S. Appl. No. 14/162,207. |
Notice of Allowance dated Sep. 1, 2017 for U.S. Appl. No. 14/162,207. |
Buchman, et al., A New Central Venous Catheter Cap: Decreased Microbial Growth and Risk for Catheter-Related Bloodstream Infection, The Journal of Vascular Access ,2009 ,11-21. |
Maki, et al., ln Vitro Studies of a Novel Antimicrobial Luer-Activated Needleless Connector for Prevention of Catheter-Related Blookstream Infection, Clinical Infection Diseases, vol. 50, Issue 12 ,Jun. 15, 2010 ,1580-1587. |
Menyhay, et al., Disinfection of Needleless Catheter Connecors and Access Ports with Alcohol May Not Prevent Microbial Entry: The Promise of a Novel Antiseptic-Barrier Cap, Infection control and Hospital Epidemiology, vol. 27 No. 1 ,Jan. 2006 ,23-27. |
Stoker, et al., One Less Problem, Safe Practrices when Administering IV Therapy, Managing Infection Control, 4 pgs ,Jun. 2008. |
European Search Report dated Jun. 9, 2020 for EP18744486.4. |
Notice of Allowance dated Apr. 6, 2021 for U.S. Appl. No. 16/150,966. |
Notice of Allowance dated Jan. 11, 2023 for U.S. Appl. No. 14/797,533. |
Dictionary.com Unabridged, Opposite, Jan. 5, 2016, Random House, Inc. |
European Search Report dated Aug. 28, 2013 for EP13175144.8. |
International Search Report and Written Opinion dated Jul. 21, 2009 for PCT/US2008/051087. |
Notice of Allowance dated Sep. 17, 2018 for U.S. Appl. No. 14/845,004. |
Notice of Allowance dated Oct. 25, 2018 for U.S. Appl. No. 14/947,341. |
Notice of Allowance dated Nov. 9, 2018 for U.S. Appl. No. 15/203,002. |
Notice of Allowance dated Dec. 19, 2019 for U.S. Appl. No. 15/979,213. |
Office Action dated Jan. 3, 2018 for U.S. Appl. No. 13/935,921. |
Office Action dated Jan. 12, 2016 for U.S. Appl. No. 13/935,921. |
Office Action dated Jan. 27, 2010 for U. S. U.S. Appl. No. 12/014,388. |
Office Action dated Feb. 14, 2017 for U.S. Appl. No. 13/935,921. |
Office Action dated Feb. 27, 2018 for U.S. Appl. No. 14/978,925. |
Office Action dated Mar. 4, 2021 for U.S. Appl. No. 14/797,533. |
Office Action dated Mar. 8, 2021 for U.S. Appl. No. 16/235,584. |
Office Action dated Mar. 27, 2019 for U.S. Appl. No. 14/797,533. |
Office Action dated Apr. 4, 2018 for U.S. Appl. No. 14/845,004. |
Office Action dated Apr. 22, 2011 for U.S. Appl. No. 12/164,310. |
Office Action dated Apr. 26, 2018 for U.S. Appl. No. 14/797,533. |
Office Action dated May 5, 2009 for U.S. Appl. No. 12/014,388. |
Office Action dated May 25, 2018 for U.S. Appl. No. 15/203,002. |
Office Action dated May 27, 2022 for U.S. Appl. No. 16/081,691. |
Office Action dated Jun. 3, 2019 for U.S. Appl. No. 14/978,925. |
Office Action dated Jun. 7, 2018 for U.S. Appl. No. 14/947,341. |
Office Action dated Jun. 9, 2011 for U.S. Appl. No. 12/171,997. |
Office Action dated Jun. 18, 2021 for U.S. Appl. No. 16/235,584. |
Office Action dated Jun. 21, 2010 for U.S. Appl. No. 12/014,388. |
Office Action dated Jun. 25, 2020 for U.S. Appl. No. 16/235,584. |
Office Action dated Jul. 17, 2019 for U.S. Appl. No. 14/797,533. |
Office Action dated Jul. 23, 2020 for U.S. Appl. No. 14/797,533. |
Office Action dated Jul. 28, 2015 for U.S. Appl. No. 13/935,921. |
Office Action dated Aug. 16, 2010 for U.S. Appl. No. 12/164,310. |
Office Action dated Aug. 21, 2017 for U.S. Appl. No. 13/935,921. |
Office Action dated Aug. 22, 2022 for U.S. Appl. No. 14/797,533. |
Office Action dated Aug. 30, 2019 for U.S. Appl. No. 15/979,213. |
Office Action dated Sep. 14, 2018 for U.S. Appl. No. 14/978,925. |
Office Action dated Sep. 27, 2016 for U.S. Appl. No. 13/935,921. |
Office Action dated Oct. 20, 2017 for U.S. Appl. No. 15/203,002. |
Office Action dated Nov. 17, 2017 for U.S. Appl. No. 14/845,004. |
Office Action dated Nov. 26, 2021 for U.S. Appl. No. 14/797,533. |
Office Action dated Nov. 29, 2018 for U.S. Appl. No. 14/797,533. |
Office Action dated Dec. 23, 2010 for U.S. Appl. No. 12/014,388. |
“Curos Port Protector”, web page from http://www.iveramed.com/, Jul. 11, 2008. |
“Kippmed Vented Non-Vented Female Luer Lock Caps”, The KippGroup,, Jan. 1, 1995, 2 pgs. |
Buchman , et al., “A New Central Venous Catheter Cap: Decreased Microbial Growth and Risk for Catheter-Related Bloodstream Infection”, The Journal of Vascular Access, Jan. 1, 2009, 11-21. |
PCT/US2017/022382 , International Preliminary Report on Patentability, Sep. 27, 2018, 10 pages. |
International Search Report and Written Opinion dated Feb. 23, 2021 for PCT/IB2020/060662. |
International Search Report and Written Opinion dated Jul. 1, 2019 for PCT/US2019/020625. |
International Search Report and Written Opinion dated Jul. 19, 2017 for PCT/US2017/022382. |
Office Action dated Apr. 17, 2020 for U.S. Appl. No. 16/081,691. |
Second Written Opinion dated Feb. 11, 2021 for PCT/IB2020/060662. |
Number | Date | Country | |
---|---|---|---|
20210016077 A1 | Jan 2021 | US |
Number | Date | Country | |
---|---|---|---|
62560808 | Sep 2017 | US | |
62451298 | Jan 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15874505 | Jan 2018 | US |
Child | 16836678 | US |